These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 2901759)
41. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
42. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Takahashi S; Sonehara K; Takagi K; Miwa T; Horikomi K; Mita N; Nagase H; Iizuka K; Sakai K Psychopharmacology (Berl); 1999 Aug; 145(3):295-302. PubMed ID: 10494578 [TBL] [Abstract][Full Text] [Related]
43. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Meltzer HY; Zhang Y; Stockmeier CA Eur J Pharmacol; 1992 May; 216(1):67-71. PubMed ID: 1388121 [TBL] [Abstract][Full Text] [Related]
44. Agonist--antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. Carlsson A; Kehr W; Lindqvist M J Neural Transm; 1977; 40(2):99-113. PubMed ID: 323424 [TBL] [Abstract][Full Text] [Related]
45. Effects of chronic haloperidol, thioridazine and zotepine treatment on apomorphine elicited stereotypic behavior and 3H-spiroperidol binding sites in the striatum of the rat. Lai HC; Carino MA; Horita A Proc West Pharmacol Soc; 1981; 24():5-6. PubMed ID: 6114496 [No Abstract] [Full Text] [Related]
46. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum. Meller E; Friedman E Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921 [TBL] [Abstract][Full Text] [Related]
47. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase. Bhargava HN Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397 [TBL] [Abstract][Full Text] [Related]
48. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats. Frey JM; Morgan WW; Ticku MK; Huffman RD Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028 [TBL] [Abstract][Full Text] [Related]
49. Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum. Friend WC; Brown GM; Jawahir G; Lee T; Seeman P Am J Psychiatry; 1978 Jul; 135(7):839-41. PubMed ID: 665797 [TBL] [Abstract][Full Text] [Related]
50. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity? Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698 [TBL] [Abstract][Full Text] [Related]
51. Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment. Young KA; Zavodny R; Hicks PB J Neural Transm Gen Sect; 1991; 86(3):223-8. PubMed ID: 1837997 [TBL] [Abstract][Full Text] [Related]
52. Enhancement of hypophysectomy-induced dopamine receptor hypersensitivity in male rats by chronic haloperidol administration. Gordon JH; Diamond BI J Neurochem; 1984 Feb; 42(2):523-8. PubMed ID: 6537969 [TBL] [Abstract][Full Text] [Related]
53. Alteration in dopaminergic and muscarinic cholinergic receptors after subchronic treatment with haloperidol in the developing rat brain. Kajiyama H; Nomura Y J Pharmacobiodyn; 1981 Feb; 4(2):85-90. PubMed ID: 7196947 [TBL] [Abstract][Full Text] [Related]
54. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320 [TBL] [Abstract][Full Text] [Related]
55. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding. Pierce RC; Rowlett JK; Bardo MT; Rebec GV Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684 [TBL] [Abstract][Full Text] [Related]
56. Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat. Deutsch SI; Halperin R; Stanley M; Davis KL Neurochem Res; 1985 Apr; 10(4):491-8. PubMed ID: 2582289 [TBL] [Abstract][Full Text] [Related]
57. Repeated treatment with (-)-sulpiride plus a low dose of SCH 23390 displays wider neuroleptic activity without inducing dopaminergic supersensitivity. Dall'Olio R; Gandolfi O; Roncada P; Vaccheri A; Montanaro N Psychopharmacology (Berl); 1990; 100(4):560-2. PubMed ID: 1969667 [TBL] [Abstract][Full Text] [Related]
59. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat. Simpson MD; Jenner P; Marsden CD Biochem Pharmacol; 1986 Oct; 35(20):3501-6. PubMed ID: 3768037 [TBL] [Abstract][Full Text] [Related]
60. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. de Graaf CJ; Korf J Psychopharmacology (Berl); 1986; 90(1):54-7. PubMed ID: 3094062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]